Seguridad de las vacunas contra la COVID-19
| dc.contributor.author | Nataniel Aldo Chaparro Mérida | |
| dc.contributor.author | Dayany Moreno Samper | |
| dc.contributor.author | Alex Omar Franco Lacato | |
| dc.coverage.spatial | Bolivia | |
| dc.date.accessioned | 2026-03-22T14:39:33Z | |
| dc.date.available | 2026-03-22T14:39:33Z | |
| dc.date.issued | 2021 | |
| dc.description | Citaciones: 12 | |
| dc.description.abstract | The development and production of safe and effective vaccines against coronavirus disease 2019 (COVID-19) provides hope for controlling the current pandemic. Adverse events following immunization are unwanted responses or unintended events that must be carefully monitored, as all vaccines, including those developed against SARS-CoV-2, are required to meet safety criteria for administration in humans. Information was collected from the PubMed/Medline database during the months of August 2020 to November 2021. Most adverse events reported in clinical trials were mild or moderate; however, thrombotic events associated with some viral vector-based vaccines against COVID-19 were identified in follow-up studies, although completion of the various ongoing studies and post-marketing surveillance is required to determine all potential adverse events, as well as those of special interest. | |
| dc.identifier.doi | 10.17843/rpmesp.2021.384.9308 | |
| dc.identifier.uri | https://doi.org/10.17843/rpmesp.2021.384.9308 | |
| dc.identifier.uri | https://andeanlibrary.org/handle/123456789/47798 | |
| dc.language.iso | es | |
| dc.publisher | National Institute of Health of Peru | |
| dc.relation.ispartof | Revista Peruana de Medicina Experimental y Salud Pública | |
| dc.source | Fundación PROINPA | |
| dc.subject | Coronavirus disease 2019 (COVID-19) | |
| dc.subject | Medicine | |
| dc.subject | Pandemic | |
| dc.subject | Adverse effect | |
| dc.subject | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) | |
| dc.subject | 2019-20 coronavirus outbreak | |
| dc.subject | Humanities | |
| dc.title | Seguridad de las vacunas contra la COVID-19 | |
| dc.type | article |